Rolf Pringler Holm

Keyphrases

1. Multiple Sclerosis 100%
2. Disease Activity 35%
3. Multiple Sclerosis Treatment 35%
4. Socioeconomic Status 32%
5. Comorbidity 32%
6. T2 Lesions 32%
7. Aging Population 32%
8. Fingolimod 32%
9. Prognostic Factors 32%
10. Teriflunomide 32%
11. Newly Diagnosed 32%
12. Single-center Study 32%
13. MS Diagnosis 32%
14. Progressive MS 32%
15. Disease Risk 29%
16. Expanded Disability Status Scale 22%
17. Relapsing-remitting multiple Sclerosis 20%
18. Diagnostic Uncertainty 17%
19. Chronic Comorbidity 16%
20. National Cohort Study 12%
21. Denmark 11%
22. Population-based Registry 10%
23. Age Groups 9%
24. Dimethyl Fumarate 8%
25. Socio-economic Data 8%
26. Cognitive Impairment 8%
27. Charlson Comorbidity Index 6%
28. Predictive Models 5%
29. Disease Reactivation 5%
30. Treatment Discontinuation 5%
31. Disease-modifying Therapy 5%
32. Two-objective 5%
33. Medical Records 5%
34. Gender Influence 5%
35. Treatment Decisions 5%
36. Differential Impact 5%
37. Lesion Load 5%
38. First Treatment 5%
39. MRI Lesions 5%
40. Clinically Isolated Syndrome 5%
41. Aging Effect 5%
42. Low Risk 5%
43. Influence of Age 5%
44. Diffusion Magnetic Resonance Imaging (dMRI) 5%